Long-acting phosphodiesterase 5 inhibitor, tadalafil, and superoxide dismutase mimetic, tempol, protect against acute hypoxia-induced pulmonary hypertension in rats

Human and Experimental Toxicology

Volumn 31, Issue 6, 2012, Pages 626-636

  Rashid, M ^a   Kotwani, A ^a   Fahim, M ^b  

^a UNIVERSITY OF DELHI   (India)

^b HAMDARD UNIVERSITY   (India)

Author keywords

acute hypoxia; phosphodiesterase 5 inhibitor; pulmonary hypertension; tadalafil; tempol

Indexed keywords

CARBOXYMETHYLCELLULOSE; GLUTATHIONE; PHOSPHODIESTERASE V; SUPEROXIDE DISMUTASE; TADALAFIL; TEMPOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; HEART OUTPUT; HEART RATE; HEART RIGHT VENTRICLE; HEART VENTRICLE CONTRACTILITY; HYPOTENSION; HYPOXIA; LIPID PEROXIDATION; MEAN ARTERIAL PRESSURE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; SYSTOLIC BLOOD PRESSURE; WISTAR ALBINO GLAXO RAT;

ANIMALS; ANOXIA; ANTIOXIDANTS; BLOOD PRESSURE; CARBOLINES; CARDIAC OUTPUT; CYCLIC N-OXIDES; HEART RATE; HEART VENTRICLES; HYPERTENSION, PULMONARY; MALONDIALDEHYDE; OXIDATIVE STRESS; PHOSPHODIESTERASE 5 INHIBITORS; RATS; RATS, WISTAR; SPIN LABELS; VASODILATION;

RATTUS; RATTUS NORVEGICUS;

EID: 84861798878     PISSN: 09603271     EISSN: 14770903     Source Type: Journal    
DOI: 10.1177/0960327111429138     Document Type: Article

References (38)

1. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004 ; 43: 13S - 24S
2. Rubin LJ. Primary pulmonary hypertension. N Engl J Med. 1997 ; 336: 111-117
3. Kessler R, Chaouat A, Weitzenblum E, Oswald M, Ehrhart M, Apprill M, et al. Pulmonary hypertension in the obstructive sleep apnea syndrome: prevalence, causes and therapeutic consequences. Eur Respir J. 1996 ; 9: 787-794
4. Chan SY, Loscalzo J. Pathogenic mechanisms of pulmonary arterial hypertension. J Mol Cell Cardiol. 2008 ; 44: 14-30
5. Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D, et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation. 2003 ; 108: 2066-2069
6. Morrell ED, Tsai BM, Crisostomo PR, Hammoud ZT, Meldrum DR. Experimental therapies for hypoxia-induced pulmonary hypertension during acute lung injury. Shock. 2006 ; 25: 214-226
7. Olschewski H, Rohde B, Behr J, Ewert R, Gessler T, Ghofrani HA, et al. Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. Chest. 2003 ; 124: 1294-1304
8. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet. 2003 ; 361: 1533-1544
9. Fink TL, Francis SH, Beasley A, Grimes KA, Corbin JD. Expression of an active, monomeric catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (PDE5). J Biol Chem. 1999 ; 274: 34613-34620
10. Giordano D, De Stefano ME, Citro G, Modica A, Giorgi M. Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain. Biochim Biophys Acta. 2001 ; 1539: 16-27
11. Wharton J, Strange JW, Møller GM, Growcott EJ, Ren X, Franklyn AP, et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med. 2005 ; 172: 105-113
12. Wilkens H, Guth A, König J, Forestier N, Cremers B, Hennen B, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation. 2001 ; 104: 1218-1222
13. Michelakis ED, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation. 2002 ; 105: 2398-2403
14. Mehrotra N, Gupta M, Kovar A, Meibohm B. The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy. Int J Impot Res. 2007 ; 19: 253-264
15. Palmieri EA, Affuso F, Fazio S. Tadalafil in primary pulmonary arterial hypertension. Ann Intern Med. 2004 ; 141: 743-744
16. Waypa GB, Chandel NS, Schumacker PT. Model for hypoxic pulmonary vasoconstriction involving mitochondrial oxygen sensing. Circ Res. 2001 ; 88: 1259-1266
17. Waypa GB, Marks JD, Mack MM. Mitochondrial reactive oxygen species trigger calcium increases during hypoxia in pulmonary arterial myocytes. Circ Res. 2002 ; 91: 719-726
18. Hodyc D, Snorek M, Brtnicky T. Superoxide dismutase mimetic tempol inhibits hypoxic pulmonary vasoconstriction in rats independently of nitric oxide production. Exp Physiol. 2007 ; 92: 945-951
19. Verit A, Savas M, Ciftci H, Aksoy N, Taskin A, Topal U. Assessment of the acute effects of tadalafil on the cardiovascular system based on examination of serum oxidative status and paraoxonase activity in men with erectile dysfunction: a preliminary study. Int J Impot Res. 2010 ; 22: 115-119
20. Nilsson UA, Olsson LI, Carling G, Bylundfellenius AC. Inhibition of lipid-peroxidation by spin labels - relationships between structure and function. J Biol Chem. 1989 ; 264: 11131-11135
21. Shahid M, Tauseef M, Sharma KK, Fahim M. Brief femoral artery ischaemia provides protection against myocardial ischaemia-reperfusion injury in rats: the possible mechanisms. Exp Physiol. 2008 ; 93: 954-968
22. Wright JR, Colby HD, Miles PR. Cytosolic factors that affect microsomal lipid peroxidation in lung and liver. Arch Biochem Biophys. 1981 ; 206: 296-304
23. Jollow D, Mitchell L, Zampaglione N. Bromobenzene induced liver necrosis: protective role of glutathione an evidence for 3,4 bromo benzenoxide as the hepatotoxic intermediate. Pharmacology. 1974 ; 11: 151-169
24. Thompson BT, Hassoun PM, Kradin RL, Hales CA. Acute and chronic hypoxic pulmonary hypertension in guinea pigs. J Appl Physiol. 1989 ; 66: 920-928
25. Huang KL, Wu CP, Kang BH, Lin YC. Chronic hypoxia attenuates nitric oxide-dependent hemodynamic responses to acute hypoxia. J Biomed Sci. 2002 ; 9: 206-212
26. Rex S, Missant C, Segers P, Wouters P. Thoracic epidural anesthesia impairs the hemodynamic response to acute pulmonary hypertension by deteriorating right ventricular-pulmonary arterial coupling. Crit Care Med. 2007 ; 35: 222-229
27. Cohen AH, Hanson K, Morris K, Fouty B, McMurty IF, Clarke W, et al. Inhibition of cyclic 3′-5′-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. J Clin Invest. 1996 ; 97: 172-179
28. Rabe KF, Tenor H, Dent G, Schudt C, Nakashima M, Magnussen H. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol. 1994 ; 266: L536 - L543
29. Raja SG, Nayak SH. Sildenafil: emerging cardiovascular indications. Ann Thorac Surg. 2004 ; 78: 1496-1506
30. Uzun O, Balbay O, Comunoǧlu NU, Yavuz O, Nihat Annakkaya A, Güler S, et al. Hypobaric-hypoxia-induced pulmonary damage in rats ameliorated by antioxidant erdosteine. Acta Histochem. 2006 ; 108: 59-68
31. Tsai BM, Turrentine MW, Sheridan BC, Wang M, Fiore AC, Brown JW, et al. Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression. Ann Thorac Surg. 2006 ; 81: 272-278
32. Serres F, Nicolle AP, Tissier R,, Gouni V, Pouchelon JL, Chetboul V. Efficacy of oral tadalafil, a new long-acting phosphodiesterase-5 inhibitor, for the short-term treatment of pulmonary arterial hypertension in a dog. J Vet Med. 2006 ; 53: 129-133
33. Kuehne T, Yilmaz S, Steendijk P, Moore P, Groenink M, Saaed M, et al. Magnetic resonance imaging analysis of right ventricular pressure-volume loops: in vivo validation and clinical application in patients with pulmonary hypertension. Circulation. 2004 ; 110: 2010-2016
34. Velez-Roa S, Ciarka A, Najem B, Vachiery JL, Naeije R, van de Borne P. Increased sympathetic nerve activity in pulmonary artery hypertension. Circulation. 2004 ; 110: 1308-1312
35. Archer SL, Yankovich RD, Chesler E, Weir EK. Comparative effects of nisoldipine, nifedipine and bepridil on experimental pulmonary hypertension. J Pharmacol Exp Ther. 1985 ; 233: 12-17
36. Candice Fike D, Yongmei Z, Mark RK. Thromboxane inhibition reduces an early stage of chronic hypoxia-induced pulmonary hypertension in piglets. J Appl Physiol. 2005 ; 99: 670-676
37. Tessler RB, Zadinello M, Fiori H, Colvero M, Belik J, Fiori RM. Tadalafil improves oxygenation in a model of newborn pulmonary hypertension. Pediatr Crit Care Med. 2008 ; 9: 330-332
38. Bremer HC, Kreisel W, Roecker K, Dreher M, Koenig D, Kurz-Schmieg AK, et al. Phosphodiesterase 5 inhibitors lower both portal and pulmonary pressure in portopulmonary hypertension: a case report. J Med Case Rep. 2007 ; 10: 1-46